Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survivin-Targeted DC Injection for Newly Diagnosed Glioblastoma
NCT07715097Phase 2Not yet recruiting
- Sponsor
- Tricision Biotherapeutics
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 2 trial of survivin-targeted DC cell injection in glioblastoma (GBM), sponsored by Tricision Biotherapeutics. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
survivin-targeted DC cell injection
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07715097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715097.